Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial (vol 376, pg 705, 2010)

被引：0
|
作者：
Kwo, P. Y.
Lawitz, E. J.
McCone, J.
机构：
来源：
LANCET | 2010年 / 376卷 / 9748期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1224 / 1224
页数：1
相关论文
共 50 条
  • [21] Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
    Lawitz, Eric
    Lalezari, Jay P.
    Hassanein, Tarek
    Kowdley, Kris V.
    Poordad, Fred F.
    Sheikh, Aasim M.
    Afdhal, Nezam H.
    Bernstein, David E.
    DeJesus, Edwin
    Freilich, Bradley
    Nelson, David R.
    Dieterich, Douglas T.
    Jacobson, Ira M.
    Jensen, Donald
    Abrams, Gary A.
    Darling, Jama M.
    Rodriguez-Torres, Maribel
    Reddy, K. Rajender
    Sulkowski, Mark S.
    Bzowej, Natalie H.
    Hyland, Robert H.
    Ho, Hongmei
    Lin, Ming
    Mader, Michael
    Hindes, Robert
    Albanis, Efsevia
    Symonds, William T.
    Berrey, Michelle M.
    Muir, Andrew
    LANCET INFECTIOUS DISEASES, 2013, 13 (05): : 401 - 408
  • [22] Boceprevir (BOC) plus peginterferon Alfa-2b/Ribavirin (PR) in the treatment of HCV genotype-1 (HCV-G1) infected asian patients in the SPRINT-1, SPRINT-2, RESPOND-2 trials
    Hu, Ke Qin
    Bognar, Fernando Alvarez
    Thompson, Seth
    Pedicone, Lisa
    Wahl, Janice
    Lim, Seng Gee
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 249 - 249
  • [23] Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial (vol 383, pg 515, 2014)
    Lawitz, E.
    Poordad, F. F.
    Pang, P. S.
    LANCET, 2014, 383 (9920): : 870 - 870
  • [24] ADHERENCE TO ASSIGNED DOSING REGIMEN AND SUSTAINED VIROLOGIC RESPONSE AMONG HEPATITIS C GENOTYPE 1 TREATMENT-NAIVE AND PEG/RIBAVIRIN TREATMENT-FAILURES TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN
    Gordon, S. C.
    Lawitz, E. J.
    Bacon, B. R.
    Sulkowski, M. S.
    Yoshida, E. M.
    Davis, M.
    Boparai, N.
    Sniukiene, V.
    Burroughs, M.
    Brass, C. A.
    Albrecht, J. K.
    Reddy, K. R.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S173 - S174
  • [25] Adherence to Assigned Dosing Regimen and Sustained Virologic Response Among Hepatitis C Genotype 1 Treatment-NaiVE and PEG/Ribavirin Treatment-Failures Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin
    Gordon, Stuart C.
    Lawitz, Eric J.
    Bacon, Bruce R.
    Sulkowski, Mark
    Yoshida, Eric M.
    Davis, Mitchell N.
    Boparai, Navdeep
    Sniukiene, Vilma
    Burroughs, Margaret
    Brass, Clifford A.
    Albrecht, Janice K.
    Reddy, Rajender
    GASTROENTEROLOGY, 2011, 140 (05) : S944 - S944
  • [26] EFFICACY AND SAFETY RESULTS OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN INTERFERON-ALFA TREATMENT NAIVE PATIENTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C
    Nelson, D.
    Benhamou, Y.
    Chuang, W. L.
    Lawitz, E.
    Flisiak, R.
    Rodriguez-Torres, M.
    Bain, V.
    Patel, K.
    Cronin, P. W.
    Pulkstenis, E.
    Subramanian, G. M.
    McHutchison, J. G.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S378 - S378
  • [27] EFFICACY AMONG NORTH AMERICAN AND EUROPEAN HCV GENOTYPE-1 TREATMENT-NAIVE AND PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN
    Marcellin, P.
    Vierling, J. M.
    Alric, L.
    Pirisi, M.
    Tran, A.
    Albrecht, J. K.
    Brass, C. A.
    Boparai, N.
    Sniukiene, V.
    Burroughs, M.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S184 - S184
  • [28] Efficacy among North American and European HCV genotype-1 treatment-naive and previous non-responders and relapsers to peginterferon/ribavirin when treated with boceprevir plus peginterferon alfa-2b/ribavirin
    Bognar, F.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 97 - 98
  • [29] Efficacy Among North American and European HCV Genotype-1 Treatment-NaiVE and Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin
    Marcellin, Patrick
    Vierling, John M.
    Alric, Laurent
    Pirisi, Mario
    Tran, Albert
    Albrecht, Janice K.
    Brass, Clifford A.
    Boparai, Navdeep
    Sniukiene, Vilma
    Burroughs, Margaret
    GASTROENTEROLOGY, 2011, 140 (05) : S945 - S945
  • [30] Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials
    Manns, Michael P.
    McCone, Jonathan, Jr.
    Davis, Mitchell N.
    Rossaro, Lorenzo
    Schiff, Eugene
    Shiffman, Mitchel L.
    Bacon, Bruce
    Bourliere, Marc
    Sulkowski, Mark S.
    Bruno, Savino
    Balart, Luis
    Bronowicki, Jean-Pierre
    Kwo, Paul
    Poordad, Fred
    Felizarta, Franco
    Reddy, K. Rajender
    Helmond, Frans A.
    Sings, Heather L.
    Pedicone, Lisa D.
    Burroughs, Margaret
    Brass, Clifford A.
    Albrecht, Janice K.
    Vierling, John M.
    LIVER INTERNATIONAL, 2014, 34 (05) : 707 - 719
12345